Medical R&D firm Celsion has received a current procedural terminology (CPT) code from the American Medical Association for its investigational thermal therapy system for ablation/reduction of malignant breast tumors, the company reported.
Based on technology developed at the Massachusetts Institute of Technology in Boston, the system uses adaptive phased-array (APA) technology to focus microwaves directly on cancerous cells in order to ablate them with targeted heat, Columbia, MD-based Celsion said.
The company said that the availability of the CPT code during clinical trials in the U.S. and Europe will allow it to accumulate reimbursement charge data from investigators during the course of the trials. This data will allow Medicare and other third-party healthcare insurance carriers to track the charges, which will form the basis of a charge profile for physicians when the APA system receives final approval from the Food and Drug Administration.
By AuntMinnie.com staff writersJuly 24, 2003
Related Reading
Celsion applies for phase II trials of breast cancer ablation system, November 10, 2002
Copyright © 2003 AuntMinnie.com
